Differential expression of calbindin in nigral dopaminergic neurons in two mice strains with differential susceptibility to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Journal of Chemical Neuroanatomy

• Publication date

  2016-10-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.jchemneu.2016.01.001PMID 26775762
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Epidemiology of neurological disorders in India: review of background, prevalence and incidence of epilepsy, stroke, Parkinson's disease and tremors.

  2014cited by this paper
• Molecular determinants of selective dopaminergic vulnerability in Parkinson’s disease: an update

  2014cited by this paper
• A Journal of Neurology

  2013cited by this paper
• Age Effects in Substantia Nigra of Asian Indians

  2013cited by this paper
• The nigrostriatal system in the presymptomatic and symptomatic stages in the MPTP monkey model: a PET, histological and biochemical study.

  2012cited by this paper
• GIRK2 expression in dopamine neurons of the substantia nigra and ventral tegmental area

  2012cited by this paper
• A cytoarchitectonic and chemoarchitectonic analysis of the dopamine cell groups in the substantia nigra, ventral tegmental area, and retrorubral field in the mouse

  2012cited by this paper
• The Neuroprotective Effect of Overexpression of Calbindin-D28k in an Animal Model of Parkinson’s Disease

  2012cited by this paper
• Vulnerability of Mesostriatal Dopaminergic Neurons in Parkinson's Disease

  2010cited by this paper
• Expression of GDNF receptors GFRalpha1 and RET is preserved in substantia nigra pars compacta of aging Asian Indians.

  2010cited by this paper
• Epidemiology of Parkinson disease in the city of Kolkata, India

  2010cited by this paper
• Ageing enhances alpha-synuclein, ubiquitin and endoplasmic reticular stress protein expression in the nigral neurons of Asian Indians.

  2010cited by this paper
• Absence of age-related changes in nigral dopaminergic neurons of Asian Indians: relevance to lower incidence of Parkinson's disease.

  2009cited by this paper
• A comparison of model-based (2D) and design-based (3D) stereological methods for estimating cell number in the substantia nigra pars compacta (SNpc) of the C57BL/6J mouse.

  2009cited by this paper
• Epidemiology of Parkinson's disease and movement disorders in India: problems and possibilities.

  2007cited by this paper
• Protocol for the MPTP mouse model of Parkinson's disease

  2007cited by this paper
• Dopamine neuron systems in the brain: an update.

  2007cited by this paper
• Regional vulnerability of mesencephalic dopaminergic neurons prone to degenerate in Parkinson's disease: a post-mortem study in human control subjects.

  2006cited by this paper
• Melanized nigral neuronal numbers in Nigerian and British individuals

  2006cited by this paper
• Cell type analysis of functional fetal dopamine cell suspension transplants in the striatum and substantia nigra of patients with Parkinson's disease.

  2005cited by this paper
• Gene expression profiling of rat midbrain dopamine neurons: implications for selective vulnerability in parkinsonism.

  2005cited by this paper
• The MPTP model of Parkinson's disease.

  2005cited by this paper
• A definition of Parkinson's disease.

  2005cited by this paper
• Cell type-specific gene expression of midbrain dopaminergic neurons reveals molecules involved in their vulnerability and protection.

  2005cited by this paper
• Prevalence and incidence of Parkinson's disease in Europe.

  2005cited by this paper
• Prevalence of Neurological Disorders in Bangalore, India: A Community-Based Study with a Comparison between Urban and Rural Areas

  2004cited by this paper
• Cardiovascular effects of methamphetamine in Parkinson's disease patients

  2004cited by this paper
• 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned model of parkinson's disease, with emphasis on mice and nonhuman primates.

  2004cited by this paper
• Parkinson's Disease Mechanisms and Models

  2003cited by this paper
• Staging of brain pathology related to sporadic Parkinson's disease.

  2003cited by this paper
• Effect of prenatal auditory enrichment on developmental expression of synaptophysin and syntaxin 1 in chick brainstem auditory nuclei.

  2002cited by this paper
• Ageing of substantia nigra in humans: 
cell loss may be compensated by hypertrophy

  2002cited by this paper
• Age‐related decreases in Nurr1 immunoreactivity in the human substantia nigra

  2002cited by this paper
• Evidence for resistance to MPTP in C57BL/6 × BALA/c F1 hybrids as compared with their progenitor strains

  2000cited by this paper
• The substantia nigra of the human brain. I. Nigrosomes and the nigral matrix, a compartmental organization based on calbindin D(28K) immunohistochemistry.

  1999cited by this paper
• Differential strain susceptibility following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) administration acts in an autosomal dominant fashion: quantitative analysis in seven strains of Mus musculus.

  1999cited by this paper
• Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine exposure

  1999cited by this paper
• The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease.

  1999cited by this paper
• Unbiased morphometrical measurements show loss of pigmented nigral neurones with ageing

  1999cited by this paper
• Low numbers and no loss of melanized nigral neurons with increasing age in normal human brains from India

  1998cited by this paper
• Neuro-epidemiological pilot survey of an urban population in a developing country. A study in Bangalore, south India.

  1996cited by this paper
• Prevalence and pattern of major neurological disorders in rural Kashmir (India) in 1986.

  1994cited by this paper
• Differences in nigral neuron number and sensitivity to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in C57/bl and CD-1 mice.

  1994cited by this paper
• Chronic MPTP treatment reproduces in baboons the differential vulnerability of mesencephalic dopaminergic neurons observed in Parkinson's disease.

  1994cited by this paper
• Calcium-binding proteins in the nervous system.

  1992cited by this paper
• Transient calbindin-D28k-positive systems in the telencephalon: ganglionic eminence, developing striatum and cerebral cortex

  1992cited by this paper
• Midbrain Dopaminergic Cell Loss in Parkinson's Disease and MPTP‐Induced Parkinsonism: Sparing of Calbindin‐D25k—Containing Cells a

  1992cited by this paper
• In vitro enzyme activation with calbindin‐D28k, the vitamin D‐dependent 28 kDa calcium binding protein

  1992cited by this paper
• Dopaminergic neurons expressing calbindin in normal and parkinsonian monkeys.

  1991cited by this paper
• Relative sparing in Parkinson's disease of substantia nigra dopamine neurons containing calbindin-D28K.

  1990cited by this paper
• Prevalence Of Common Neurological Diseases In A Rural Community Of India

  1989cited by this paper
• The mechanism of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity: role of intracellular calcium.

  1988cited by this paper
• IV. MPTP, MPP+ and mitochondrial function

  1987cited by this paper
• MPTP, MPP+ and mitochondrial function.

  1987cited by this paper
• The neostriatal mosaic: compartmental distribution of calcium-binding protein and parvalbumin in the basal ganglia of the rat and monkey.

  1985cited by this paper

• Enrichment-induced behavioural changes in MPTP mice

  2025cites this paper
• Stigmasterol exerts antioxidant effects through activation of the Keap1/Nrf2 signaling pathway in Parkinson’s disease model

  2025cites this paper
• Lactiplantibacillus plantarum as a Psychobiotic Strategy Targeting Parkinson’s Disease: A Review and Mechanistic Insights

  2025cites this paper
• Unrevealing the molecular mechanisms of MPTP-induced Parkinson’s in experimental animals

  2025cites this paper
• An update on drug repurposing in Parkinson's disease: Preclinical and clinical considerations.

  2025cites this paper
• Apoptotic factors and mitochondrial complexes assist determination of strain-specific susceptibility of mice to Parkinsonian neurotoxin MPTP

  2022cites this paper
• Differences in Neuronal Numbers, Morphology and Developmental Apoptosis in Mice Nigra Provide Evidence of Ontogenic Origin of Vulnerability to Parkinson’s Disease

  2021cites this paper
• ALS-CSF-induced structural changes in spinal motor neurons of rat pups cause deficits in motor behaviour

  2020cites this paper
• Differences in Neuronal Numbers, Morphology, and Developmental Apoptosis in Mice Nigra Provide Experimental Evidence of Ontogenic Origin of Vulnerability to Parkinson’s Disease

  2020cites this paper
• MPTP-induced mouse model of Parkinson’s disease: A promising direction for therapeutic strategies

  2020cites this paper
• Small molecule modulator of aggrephagy regulates neuroinflammation to curb pathogenesis of neurodegeneration

  2019cites this paper
• Role of the endolysosomal system in Parkinson’s disease

  2019cites this paper
• Divergent Expression Patterns of Drp1 and HSD10 in the Nigro-Striatum of Two Mice Strains Based on their MPTP Susceptibility

  2019cites this paper
• Admixing MPTP‐resistant and MPTP‐vulnerable mice enhances striatal field potentials and calbindin‐D28K expression to avert motor behaviour deficits

  2019cites this paper
• Diabetes, a Contemporary Risk for Parkinson’s Disease: Epidemiological and Cellular Evidences

  2019cites this paper
• Modulation of Autophagy by a Small Molecule Inverse Agonist of ERRα Is Neuroprotective

  2018cites this paper
• Pluchea lanceolata protects hippocampal neurons from endothelin-1 induced ischemic injury to ameliorate cognitive deficits.

  2018cites this paper
• Baseline striatal and nigral interneuronal protein levels in two distinct mice strains differ in accordance with their MPTP susceptibility.

  2018cites this paper
• Investigating chondroitin sulphate proteoglycans as a therapeutic target for Parkinson's disease

  2017cites this paper
• Admixing of MPTP-Resistant and Susceptible Mice Strains Augments Nigrostriatal Neuronal Correlates to Resist MPTP-Induced Neurodegeneration

  2016cites this paper